

Undeniable neuroimmunology

Abstract

The effective therapy for illnesses associated to the excess, or lack, of immunological response depends on the advances in knowledge about the effects of neurotransmitters on the leukocytes activity. The HPA axis and the autonomous nervous system control inflammation, while certain substances secreted locally by peripheral nervous system tend to enhance the inflammatory response. In this last case, possibly as a support mechanism to the elimination of an infectious agent. Data available on the literature are still scarce, but they already emphasize the Neuroimmunology as a promising field of investigation and, above all, necessary.

Keywords: neuroimmunology, VIP, inflammation, IS, immune system, CRH, leukocytes, HPA axis

Volume 3 Issue 2 - 2016

Flavia Garcia

Department of Immunology, Brazil

Correspondence: Flavia Garcia, Department of Immunology, Centro de Hematologia e Hemoterapia - HEMOCENTRO de Campinas, São Paulo, Brazil, Tel 551935218385, Email flaviag@yahoo.com

Received: January 28, 2016 | **Published:** February 22, 2016

Abbreviations: IS, immune system; NS, nervous system; HPA, hypothalamus-hypophysis-adrenal axis; CRH, corticotrophin releasing hormone; ACTH, adreno cortico tropic hormone; VIP, vasoactive intestinal peptide

Introduction

The functional imbalance of the Immune System (IS) can express itself, basically, in two different and conflicting ways: through the lack or over response. The commitment of the IS protective capacity causes susceptibility to infections and neoplasms; while the exacerbated reactivity to its own components or to innocuous substances justifies the incidence of autoimmune diseases and allergies.

It's not a surprise that the regulation and the recovery of the homeostasis of the IS are the most pursued objectives by researchers who work in the Immunology area. However, despite the benefits originated from some immuno modulation strategies, the majority of the immunologic reactivity control medical practices is still done with antigen non-specific immuno suppresses.^{1,2} And, in the case of hyper activity, the treatments are based on the combat to the consequences of the pathology, in such a way that opportunist infections are treated with microbicides,³ and tumor cells are removed through chemical or surgical procedures.^{4,6}

It's possible that the major progresses in the capacity of manipulation of the immune response depend on the set of therapeutic agents that fulfill the integration of the immune system with other systems, particularly with the Nervous System (NS). In this article, a survey is done on some of the main information generated in the researches on neuroimmunomodulation, as well as a brief discussion regarding the physiologic implications that result from the conservation of receptors and connectors between distinct cellular types.

History of the mind- immune system link

The first empirical evidences about the existence of interactions between the NS and the IS date back to 200 C.E. and come from observations, made by the Greek doctor Galeno, that melancholic women were more susceptible to the development of breast cancer. Long after, other studies revealed that newly widowed women with a criterion to depressive syndromes had a reduction in the functional capacity of the lymphocytes; and researches done with experimental animals, under social stress, unveiled some of the impacts which psychic disturbance may cause on cells and organs of the immune system.^{7,8} Currently, the available data on the "neuroimmune axis"

already enable some authors argue inflammation as a risk factor for the development of mood disorder.⁹⁻¹¹

Molecular bases of the communication between the NS and the IS

The identification of the receptors and the connector's common to leukocytes and to neurons¹²⁻¹⁷ has clarified which are the molecules that allow the inter-systems communication. Indeed, it's already known that the bidirectional transmission of messages between the IS and the NS it's done by molecules classically known as neurotransmitters, neuropeptides, cytokines and chemokines. Therefore, leukocytes were discovered to be a source of corticotrophin releasing hormone,¹² endorphins¹³ and neuropeptides.¹⁴ Besides, expressing cholinergic receptors, adrenergic and serotonergic.¹⁵⁻¹⁷ Mutually, it's already known the fact that neurons synthesize several types of cytokines and chemokines, and express their respective receptors.¹⁸

Leukocytes & Hypothalamus & HPA axis

One of the better known "immune-neuro-immune" signaling circuits manifests itself, clinically, as fever. The rising of the body temperature it's provoked by the direct or indirect action of certain cytokines, such as TNF- α , IL1- β , IL-6 e IFN. These endogenous pyrogens induce to the synthesis of prostaglandin E2 that, on the other hand, act on the hypothalamic thermoregulatory centers causing effects that culminate in thermo genesis.¹⁹

In another function involving the hypothalamus, on the hypothalamus-hypophysis-adrenal axis (HPA), which is responsible for the response to different internal and external stimuli, there is also regulation by cytokines. The activity of the HPA axis is measured by the hormones and controlled by negative feedback. The Corticotrophin Releasing Hormone (CRH)- secreted by the hypothalamus as a response to stress- stimulates the pituitary gland to release the adreno cortico tropic hormone (ACTH), which acts on cortex of the adrenal glands inducing them to secrete a powerful glucocorticoid immunosuppressive, the cortisone. The interleukin-1 (IL-1), for instance, can interfere on the HPA axis by the stimulus to the releasing of CRH by the hypothalamus or via direct stimulus on the adrenals.

Furthermore, as it was suggested by some authors, since the leukocytes also produce ACTH, CRH and endorphins, it's plausible that the operation of the HPA axis can also get under the influence of this hormonal source. As there is also the possibility of leukocytes

constituting an alternative axis to the HPA axis. Nevertheless, it's not clear yet if the leukocyte originated hormones are able to have endocrine action, if its actions are strictly autocrine and paracrine or, still, if the high mobility of the leukocytes can compensate the quantitative limits on the production of hormones by these white cells.²⁰

Autonomous nervous system & leukocytes

The regulation of the leukocytes activity by cholinergic and adrenergic fibers it's a still partially comprehended function. In any way, there are several studies indicating the importance of this control via.

The autonomous nervous system seems to negatively regulate the inflammation. Both the sympathetic nervous system and the parasympathetic nervous system, after being stimulated by pro-inflammatory innate immune constituents, exert anti-inflammatory actions on the cells of the IS. The sympathetic nervous system can act in a more local way, through the intervention of lymphoid organs, or in a systemic manner by the stimulation of the adrenal medulla to release adrenaline in the blood. There are reports in the literature showing that this catecholamine inhibits the leukocyte synthesis of cytokines such as the IL-1, IL-6, IL-12 and TNF,²¹ at the same time that it stimulates the production of the anti-inflammatory cytokine IL-10.²²

The parasympathetic nervous system, conversely, has also showed anti-inflammatory actions over the leukocytes. Tracey demonstrated that the secretion of TNF- α by macrophages can be inhibited by the acetylcholine, having already denominated this effect as the "cholinergic anti-inflammatory pathway".²³

Peripheral nervous system & leukocytes

The majority of the substances released by the peripheral nervous system seems to have a pro-inflammatory effect on the cells of the IS. Moreover, the CRH-that in the HPA axis contributes to the stimulation of anti-inflammatory mediators-when released by nerve endings, shows pro-inflammatory effect on macrophages and lymphocytes.²⁴

Similarly, the P substance released by the peripheral nerves induces to the production of pro-inflammatory cytokines by macrophages and eosinophils.^{25,26} On the other hand, the vasoactive intestinal peptide (VIP) appears to be an exception. The VIP causes inhibition of the synthesis of the pro-inflammatory cytokines by mononuclear cells,²⁷ reduces the expression of receptors similar to Toll (TLRs) over epithelial cells,²⁸ besides stimulating the production of the anti-inflammatory cytokine IL-10 by macrophages.²⁹

Serotonin & leukocytes

The serotonin (5HT) is one monoamine which can have different effects depending on its concentration and depending on the receptor that it is linked to. In the brain, the serotonin acts as a neurotransmitter capable of interfering in behavioral and cognitive functions.³⁰

The cells of the immune system possess all the components of the serotonergic system, having the necessary machinery to not only be sensitive to serotonin, but also to produce and catabolize this amine.³¹ Despite of attending to "molecular prerequisites", the action of the serotonin on the modulation of the immune response is still underexplored. What it's known is that it can induce to changes in the profile of the leukocyte secreted cytokines.³¹ Besides, some studies suggest the existence of a complex cross-communication mechanism between the signaling triggered by 5-HT receptors and the signaling induced by molecular pattern recognition receptors.³² In this sense,

it was demonstrated that the signaling via Toll type receptors can regulate the action of the serotonin on the smooth muscle by modifying the expression of receptors to the substance.³³ Conversely, in another study, it was verified that the treatment of murine with Paliperidone, an antagonist drug of the 5-HT₂ receptor, it's capable of preventing the activation path of TLR-4.³⁴

Conclusion

The results of studies on the interactions and existing molecular coincidences between IS and the NS denounce the size of our negligence when analyzing these systems as independent entities. At the same time, they show that there is an emergent investigation field that promises the development of new therapeutic modalities.

Acknowledgments

None.

Conflicts of interest

Author declares that there is no conflict of interest.

References

- Buttgereit F, Scheffold A. Rapid glucocorticoid effects on immune cells. *Steroids*. 2002;67(6):529–534.
- Goodkin DE. Interferon beta treatment for multiple sclerosis: persisting questions. *Multiple Sclerosis*. 1996;1(6):321–324.
- Green KD, Garneau-Tsodikova S. Resistance in tuberculosis: what do we know and where can we go? *Front Microbiol*. 2013;4:208.
- Tate MC. Surgery for gliomas. *Cancer Treat Res*. 2015;163:31–47.
- Kershaw MH, Devaud C, John LB, et al. Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment. *Oncimmunology*. 2013;2(9):e25962.
- Franceschini G, Martin Sanchez A, Di Leone A, et al. New trends in breast cancer surgery: a therapeutic approach increasingly efficacy and respectful of the patient. *G Chir*. 2015;36(4):145–152.
- Zisook S, Shuchter SR, Irwin M, et al. Bereavement, depression, and immune function. *Psychiatry Research*. 1994;52(1):1–10.
- Costa-Pinto FA, Palermo-Neto J. Neuroimmune interactions in stress. *Neuroimmunomodulation*. 2010;17(3):196–199.
- Hashimoto K. Inflammatory biomarkers as differential predictors of antidepressant response. *Int J Mol Sci*. 2015;16(4):7796–7801.
- Pavlov VA, Wang H, Czura CJ, et al. The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation. *Molecular Medicine*. 2003;9(5-8):125–134.
- Fonseka TM, McIntyre RS, Soczynska JK, et al. Novel investigational drugs targeting IL-6 signaling for the treatment of depression. *Expert Opin Investig Drugs*. 2015;24(4):459–475.
- Ekman R, Servenius B, Castro MG, et al. Biosynthesis of corticotropin-releasing hormone in human T-lymphocytes. *J Neuroimmunol*. 1993;44(1):1–13.
- Blalock JE, Smith EM. Human leukocyte interferon: Structural and biological relatedness to adrenocorticotrophic hormone and endorphins. *Proc Natl Acad Sci U S A*. 1980;77(10):5972–5974.
- Garcia F, Lepelletier Y, Smaniotto S, et al. Inhibitory effect of semaphorin-3A, a known axon guidance molecule, in the human thymocyte migration induced by CXCL12. *J Leuk Biol*. 2012;91(1):7–13.

15. Sato KZ, Fujii T, Watanabe Y, et al. Diversity of mRNA expression for muscarine acetylcholine receptor subtypes and neuronal nicotinic acetylcholine receptor subunits in human mononuclear leukocytes and leukemic cell lines. *Neurosci Lett*. 1999;266(1):17–20.
16. Hadden JW, Hadden EM, Middleton E. Lymphocyte blast transformation. I. Demonstration of adrenergic receptors in human peripheral lymphocytes. *Cell Immunology*. 1970;6:583–595.
17. Durk T, Panther E, Muller T, et al. 5-Hydroxytryptamine modulates cytokine and chemokine production in LPS-primed human monocytes via stimulation of different 5-HTR subtypes. *International Immunology*. 2005;17(5):599–606.
18. Bajetto A, Bonavia R, Barbero S, et al. Characterization of chemokines and their receptors in the central nervous system: physiopathological implications. *J Neurochem*. 2002;82(6):1311–1329.
19. Dinarello CA, Gatti S, Bartfai T. Fever: Links with an ancient receptor. *Curr Biol*. 1999;9(4):147–150.
20. Blalock JE, Smith EM. Conceptual development of the immune system as a sixth sense. *Brain, Behavior, and Immunity*. 2007;21(1):23–33.
21. Van der Poll T, Jansen J, Endert E, et al. Noradrenaline inhibits lipopolysaccharide-induced tumour necrosis factor and interleukin 6 production in human whole blood. *Infect Immun*. 1994;62(5):2046–2050.
22. Woiciechowsky C, Asadullah K, Nestler D, et al. Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury. *Nature Med*. 1998;4(7):808–813.
23. Czura CJ, Friedman SG, Tracey KJ. Neural inhibition of inflammation: the cholinergic anti-inflammatory pathway. *Journal of Endotoxin Research*. 2003;9(6):409–413.
24. Agelaki S, Tsatsanis C, Gravanis A, et al. Corticotropin-releasing hormone augments proinflammatory cytokine production from macrophages in vitro and in lipopolysaccharide-induced endotoxin shock in mice. *Infect Immun*. 2002;70(11):6068–6074.
25. Cuesta MC, Quintero L, Pons H, et al. Substance P and calcitonin gene-related peptide increase IL-1 β , IL-6 and TNF α secretion from human peripheral blood mononuclear cells. *Neurochem Int*. 2002;40(4):301–306.
26. Lotz M, Vaughan JH, Carson DA. Effect of neuropeptides on production of inflammatory cytokines by human monocytes. *Science*. 1988;241(4870):1218–1221.
27. Hernanz A, Tato E, De la Fuente M, et al. Differential effects of gastrin-releasing peptide, neuropeptide Y, somatostatin and vasoactive intestinal peptide on interleukin-1 β , interleukin-6 and tumour necrosis factor- α production by whole blood cells from healthy young and old subjects. *J Neuroimmunol*. 1996;71(1-2):25–30.
28. Gomariz RP, Arranz A, Abad C, et al. Time-course expression of Toll-like receptors 2 and 4 in inflammatory bowel disease and homeostatic effect of VIP. *J Leukoc Biol*. 2005;78(2):491–502.
29. Delgado M, Munoz-Elias EJ, Gomariz RP, et al. Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. *J Immunol*. 1999;162(3):1707–1716.
30. Jenkins TA, Nguyen JC, Polglaze KE, et al. Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis. *Nutrients*. 2016;8(1):E56.
31. Arreola R, Becerril-Villanueva E, Cruz-Fuentes C, et al. Immunomodulatory effects mediated by serotonin. *J Immunol Res*. 2015;2015:354957.
32. Szabo A. Psychedelics and immunomodulation: novel approaches and therapeutic opportunities. *Frontiers in Immunology*. 2015;6:358.
33. Forcen R, Latorre E, Pardo J, et al. Toll-like receptors 2 and 4 modulate the contractile response induced by serotonin in mouse ileum: analysis of the serotonin receptors involved. *Neurogastroenterol Motil*. 2015;27(9):1258–1266.
34. MacDowell KS, Caso JR, Martín-Hernández D, et al. Paliperidone Prevents Brain Toll-Like Receptor 4 Pathway Activation and Neuroinflammation in Rat Models of Acute and Chronic Restraint Stress. *Int J Neuropsychopharmacol*. 2015;18(3).